Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Prostate cancer that is resistant to castration has been a prominent health challenge in the
lives of men, particularly older men. This study looks at the spectroscopic properties, density …

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling
continues to be the mainstay treatment of advanced-stage prostate cancer. The use of …

Metastatic castration-resistant prostate cancer (CRPC) is a fatal disease, primarily resulting
from the transcriptional addiction driven by androgen receptor (AR). First-line CRPC …

Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic
and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA …

Prostate cancer is the second leading cause of cancer death among men in the United
States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug …

Background Aberrant activation of androgen receptor signalling following castration therapy
is a common clinical observation in prostate cancer (PCa). Earlier, we demonstrated the role …

Background Castration-resistant prostate cancer (CRPC) is one of the main causes of male
cancer mortality. There is currently no effective treatment to cure this deadly prostate cancer …

Novel thiohydantoin derivatives were designed as androgen antagonists based on the
binding pattern of enzalutamide to the androgen receptor that avoided the bifurcated …

Castration resistance is a lethal form of treatment failure of prostate cancer (PCa) and is
associated with ligand-independent activation of the androgen receptor (AR). It is only …